Anti-TNF-  therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients

Abstract

Anti-TNF-α therapy is effective and relatively safe in refractory BD uveitis.

Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients

“…A recent literature review regarding the use of anti-TNF agents in 369 BD patients, showed that 89% of patients with uveitis treated with IFX presented a sustained response [8]. In a large cohort of 124 patients with refractory BD-associated uveitis, treatment with IFX or ADA led to remission of uveitis at 1 year in 67.7% of cases [28]. In the present study, retinal vasculitis was a pejorative factor for complete response on anti-TNF treatment, with 3 times decrease odds of complete remission.…”

Interleukin-37 expression is decreased in Behçet's disease and is associated with inflammation

“…Published data have shown that blocking inflammatory cytokines significantly improved the evolution of BD patients [17,34,35]. Touzot et al showed that IFN-␣ promotes a regulatory Th1 response through IL-10 secretion [17].…”

“…Touzot et al showed that IFN-␣ promotes a regulatory Th1 response through IL-10 secretion [17]. Calvo-Rio et al, reported that anti-TNF-␣ therapy is effective and relatively safe in refractory BD uveitis [35]. In addition, refractory neuro-BD patients treated with tocilizumab (anti-IL-6 receptor antibody) resulted in significant clinical improvement [36].…”

Orbital inflammatory disease management

“…Hence, initial therapy with pulse dose IV steroids is recommended in patients with Bechet's who experience new onset orbital inflammation or myositis. With regard to maintenance therapy of orbital Bechet's, there is a paucity literature; however, good longterm control has been noted with anti-TNF agents, like infliximab [117][118][119][120], and more recently with interleukin(IL)-1 inhibitors, like Anakinra [121,122], in patients with systemic disease.…”